Anthera Pharmaceuticals Receives $3 Million From Cystic Fibrosis Foundation Therapeutics To Develop Sollpura
Anthera Pharmaceuticals recently announced that it received a $3 million award from the Cystic Fibrosis Foundation Therapeutics to support both the manufacturing and clinical development of Sollpuraâ„¢ (liprotamase), Anthera’s new pancreatic enzyme replacement therapy. Cystic Fibrosis Foundation Therapeutics is an affiliate of the Cystic Fibrosis Foundation, a non-profit organization. Anthera Pharmaceuticals is a…